Stocks fall to start the trading week 📉

[Image](www.elitetrade.club) Good Afternoon! Hey, everyone. It's Adam from Elite Trade Club. Happy Monday! It's June 26th. I hope you had a great trading session. Here's what moved the market today: Markets 📈 Stocks closed lower on Monday, led by a sell-off in tech stocks. The Dow [<0.1%] edged lower, while the S&P 500 [-0.4%] lost about half a point. The Nasdaq [-1.1%] declined more than a point, and the Russell 2K [+0.1%] surprised with a small gain. Sponsored [A 100% Win Rate In 2022...]( 📈 The next 10 minutes could change your life. This reclusive millionaire hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. [Click here to see how he does it]( Today's Market-Moving News 🔎 📉 Quiet Day in the Market Stocks closed lower in a relatively quiet trading session, despite a wild weekend that almost saw a civil war break out in Russia. However, the Russia news didn't really impact markets. Instead, today's declines seemed to be the result of worsening investor sentiment stemming from the expectation of more rate hikes in the months ahead, continuing last week's theme. Today's Top Winners and Losers 🔥 FibroGen [FGEN] $2.71 (83.1%) announced it will discontinue a Phase 3 trial of pamrevlumab in lung disease patients after the drug candidate failed to meet its primary endpoint. GSR II Meteora SPAC [GSRM] $4.87 (29.8%) Filed a Form 8-K discussing non-redemption agreements from major shareholders. The SPAC's shareholders will vote on a proposed combination with Bitcoin Depot later this week. C3is [CISS] $1.85 (29.6%) fell for the second day in a row after releasing its Q1 financial and operating results on Friday. TRxADE Health [MEDS] $16.36 (+93.8%) agreed to a business combination with Superlatus. Superlatus will receive 3.8 million shares of MEDS at $58.61 per share. MoonLake Immunotherapeutics [MLTX] $45.95 (+77.5%) said a Phase 2 trial of Nanobody sonelokimab for hidradenitis suppurativa met its primary endpoint. Chemomab Therapeutics [CMMB] $1.28 (+28.0%) presented new data reinforcing CM-101's potential as a novel treatment for primary sclerosing cholangitis at a European medical conference. That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback from our members! Thanks for reading. I'll see you at the next open! Best Regards, Adam G. -- Elite Trade Club P.S... Text ELITE to 47121 to get our watchlists sent directly to your phone! You can also text CLOSE to 47121 to get the Closing Bell Roundup, too! *Standard message/carrier rates may apply. © Elite Trade Media LLC, 2023. All rights reserved. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails. [Bots click here]( 1969 Alafaya Trail Suite #247 Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](